Quick Answer
ASCENTAGE PHARMA GROUP INTERNATIONAL reported R&D Expense of $947.25 million for fiscal year 2024.
ASCENTAGE PHARMA GROUP INTERNATIONAL — Key Financials by Year
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| R&D Expense | $947.25M +34.0% |
$706.97M -4.9% |
$743.10M |
| Gross Profit | $951.57M +397.1% |
$191.44M +2.0% |
$187.71M |
- ASCENTAGE PHARMA GROUP INTERNATIONAL reported R&D Expense of $947.25 million for fiscal year 2024.
- ASCENTAGE PHARMA GROUP INTERNATIONAL showed an increase of +34.0% in R&D Expense compared to the prior fiscal year.
- ASCENTAGE PHARMA GROUP INTERNATIONAL reported Gross Profit of $951.57 million for fiscal year 2024.
- ASCENTAGE PHARMA GROUP INTERNATIONAL showed an increase of +397.1% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: